The largest increase was reported by Antibiotice Iasi in 2022 following a 31% growth which generated RON482 million in sales revenue.
Raw material costs for Antibiotice Iasi surged almost 50% to nearly RON110 million in 2022 from RON74.2 million in 2021. The company aims to double its turnover until 2030 and boost exports up to 50% of the turnover. In 2022, Antibiotice made RON184.1 million from exports, which accounts for 38% of the total sales revenue of 2022.
Following an increase of almost 16%, Biofarm Bucuresti reached revenue of over RON276 million in 2022, the first complete year in which two drug factories operated under the same umbrella. In 2021, Biofarm had inaugurated a new production facility, also in Bucharest, while keeping the production capacity it already had in Bucharest. The new production facility covers over 10,000 square meters and has four production flows. The company had originally invested EUR35 million to which it added EUR10 million. Biofarm officials expect the company’s turnover to double in the next five years.
Zentiva SA also saw a 10% growth, up to almost RON754 million in turnover in 2022. The company has two drug factories in Bucharest after the Zentiva Group, held by investment fund Advent Interna¬tio¬nal, had taken over the operations in Central and Eastern of pharmaceutical company Alvogen, in 2019. The transaction also included the Labormed factory in Bucharest, which entered Zentiva’s portfolio.
The Romanian medicine market reached RON25.7 billion in 2022, up 22% versus 2021, as per data from market research company Cegedim. The local drug production relies on 158 companies which generated a turnover of RON4.8 billion in 2021, up 6% versus 2020, as per Trade Register data.